株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

北米と欧州の製薬業界における運転資本管理

Working Capital Management in the North American and European Pharmaceutical Industry

発行 Frost & Sullivan 商品コード 327765
出版日 ページ情報 英文 52 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
北米と欧州の製薬業界における運転資本管理 Working Capital Management in the North American and European Pharmaceutical Industry
出版日: 2015年04月01日 ページ情報: 英文 52 Pages
概要

当レポートでは、北米と欧州の製薬業界における運転資本管理について調査分析し、運転資本効率と前年比成長率、収益範囲別の主要企業などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 効率的な運転資本管理に対する根拠

  • 利益性の低下
  • イノベーションモデルの失敗
  • 市場への新規参入
  • 価格プレミアムの圧力

第4章 収益範囲:収益100億米ドル超

  • 収益成長率
  • 在庫回転日数
  • 仕入債務回転日数
  • 売上債権回転日数
  • 現金循環化日数

第5章 収益範囲:収益10億〜100億米ドル

  • 収益成長率
  • 在庫回転日数
  • 仕入債務回転日数
  • 売上債権回転日数
  • 現金循環化日数

第6章 収益範囲:収益5,000万〜10億米ドル

  • 収益成長率
  • 在庫回転日数
  • 仕入債務回転日数
  • 売上債権回転日数
  • 現金循環化日数

第7章 結論

  • 結論

第8章 付録

第9章 FROST & SULLIVANについて

目次
Product Code: NEAF-01-00-00-00

Optimization is the Key to Working Capital Efficiency

This study analyzes the various working capital components in the pharmaceutical industry. The analysis has been done across the North American and European regions. Companies have also been analyzed for their working capital efficiency and year-on-year growth during the study period 2009 to 2013. The analysis includes various components of working capital management such as days inventory outstanding, days payable outstanding, days sales outstanding and cash conversion cycle. The study also analyzes the participants in the pharmaceutical industry based on their revenue ranges. It also covers the various trends that impact working capital performance of the participants in the pharmaceutical industry.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary
  • 2. Key Terms Used in the Study

2. INTRODUCTION

  • 1. Objectives of the Study
  • 2. Research Objective
  • 3. Research Objective (continued)
  • 4. Research Methodology

3. THE KEY RATIONALE FOR EFFECTIVE WORKING CAPITAL MANAGEMENT

  • 1. Decreasing Profitability
  • 2. Fizzling Innovation Model
  • 3. Access to New Markets
  • 4. Price Premium Pressure

4. REVENUE RANGE CLASSIFICATION: REVENUE GREATER THAN $10.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

5. REVENUE RANGE CLASSIFICATION: REVENUE BETWEEN $1.00 BILLION AND $10.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

6. REVENUE RANGE CLASSIFICATION: REVENUE BETWEEN $50.0 MILLION AND $1.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

7. CONCLUSIONS

  • 1. Conclusion

8. APPENDIX

  • 1. Revenue Range Classification: Revenue Greater Than $10.00 Billion
  • 2. Revenue Range Classification: Revenue Between $1.00 Billion and $10.00 Billion
  • 3. Revenue Range Classification: Revenue Between $1.00 Billion and $10.00 Billion (continued)
  • 4. Revenue Range Classification: Revenue Between $50.0 Million and $1.00 Billion
  • 5. Revenue Range Classification: Revenue Between $50.0 Million and $1.00 Billion (continued)
  • 6. Key Liquidity Ratios
  • 7. Key Liquidity Ratios (continued)
  • 8. Legal Disclaimer

9. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top